GRADE 3A FOLLICULAR LYMPHOMA

This early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in patients whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to previous treatments. The main goal is to find the safest and most effective dose of the dru…

This study is testing the safety and effectiveness of combining two existing drugs, nivolumab and lenalidomide, for patients with non-Hodgkin or Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal is to see if using these drugs together can bet…

This study tested a daily pill called ibrutinib in 41 patients with follicular lymphoma, a type of blood cancer, that had returned or stopped responding to previous treatments. The main goal was to see how well the drug could shrink the cancer and control the disease. Researchers…

This study is testing several new drug combinations to see which works best for adults with follicular lymphoma, a type of blood cancer, that has come back early or did not respond to their first round of treatment. Participants are assigned to receive one of three different trea…

This study is testing whether adding a pill called acalabrutinib makes a powerful cell therapy (CAR-T) work better and safer for people with certain aggressive B-cell lymphomas. The trial enrolled 23 adults to see if the combination is safe and can help control the cancer. Resear…

This study is testing how well two targeted drugs, obinutuzumab and ibrutinib, work together as the first treatment for people with certain slow-growing types of non-Hodgkin's lymphoma. The goal is to control the cancer by stopping cancer cells from growing and spreading, potenti…